-

Okta, Inc. Investor News: Robbins LLP is Investigating Okta, Inc. (OKTA) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Okta, Inc. (NASDAQ: OKTA) and its officers and directors to determine if they breached their fiduciary duties and violated securities laws by failing to disclose its security breach to investors. Okta provides identity solutions for enterprises, small and medium-sized business, universities, non-profits, and government agencies in the U.S. and internationally. Following its merger with Auth0, Inc. on May 3, 2021, Okta began providing additional Auth0 products related to cybersecurity and login solutions.

If you would like more information about our investigation of Okta, Inc.'s misconduct, click here.

What is this Case About: According to the complaint against Okta, during the class period, defendants made false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, defendants failed to disclose that Okta had inadequate cybersecurity controls, and as a result, its systems were vulnerable to data breaches. Okta ultimately did experience a data breach caused by a hacking group, which potentially affected hundreds of Okta customers. Okta initially did not disclose and subsequently downplayed the severity of the data breach. When Okta revealed the occurrence of the breach, Okta's stock price fell $2.98 per share, to close at $166.43 per share on March 22, 2022. Then, Raymond James downgraded Okta from "strong buy" to "market perform," noting, among other things, that "[w]hile partners were willing to trust Okta's track record, the handling of its latest security incident adds to our mounting concerns." Following this downgrade, the Company's stock price fell $17.88 per share, or more than 10%, to close at $148.55 per share on March 23, 2022.

Next Steps: If you acquired shares of Okta, Inc. (OKTA) securities between March 5, 2021 and March 22, 2022, you have legal options. Contact Robbins LLP for more information.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:
Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Okta, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:OKTA

Release Summary
Robbins LLP is Investigating Okta, Inc.'s (OKTA) Failure to Disclose its Security Breach on Behalf of Shareholders
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Robbins LLP Urges GOSS Stockholders to Contact the Firm for Information About the Class Action Against Gossamer Bio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.For more information, submit a form, email att...

Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? January 19, 2026 – March 25, 202...

Robbins LLP Reminds ALDX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Case Against Aldeyra Therapeutics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026. Defendant Aldeyra describes itself as a “biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases.” Pertinent to this action is reproxalap, which is a novel reactive aldehyde species (RASP) inhib...
Back to Newsroom